Abstract:Abstract Introduction: Paclitaxel (TaxolTM) is a blockbuster chemotherapy used for solid tumors including breast cancer. In triple-negative breast cancer (TNBC), nab-paclitaxel plus PD-L1 inhibitor, atezolizumab, is now approved based on increased survival compared with nab-paclitaxel alone. We hypothesize that there may be an interaction by which taxane therapy is immunogenic. Paclitaxel induces aberrant cell division on multipolar spindles, which often results in formation of multiple small nuclei. Some of these resemble micronuclei. Here, we test the hypothesis that taxane-induced micronuclei activate cGAS-STING to increase immunogenicity in TNBC. Methods: We evaluate the impact of clinically relevant doses of paclitaxel on TNBC cell lines MDA-MB-231, MDA-MB-453, MDA-MB-468, BT-549 and HCC-1806 on generating micronuclei by immunofluorescence microscopy. Using immunoblotting and qPCR, we evaluate the impact of paclitaxel on cGAS recruitment and activation, STING activation, and interferon-beta production. Furthermore, we co-culture MDA-MB-231 and THP-1 cells to evaluate the impact of paclitaxel on polarization of THP-1 macrophages. We employ CRISPR-mediated cGAS knockout to evaluate its role in mediating these effects. Finally, we test the effect of neoadjuvant paclitaxel (80 mg/m2 qw, 16 treatments/4 cycles) in 4 patients for formation of micronuclei and tumor-infiltrating lymphocytes 20 hours after the third treatment of paclitaxel by H&E. Results: We observe that post-mitotic cells often contain micronuclei. cGAS recruitment is detected in some micronuclei, more commonly in multinucleated cells. With three days of paclitaxel, the cGAS-positive cell population increases from 9% (+/- 1.3) to 34% (+/- 2.4) in MDA-MB-231. Similar trends are observed in other cell lines. In MDA-MB-231 cells, synthesis of 2'3'-cGAMP and IFN-beta is increased after paclitaxel. Upregulation of interferon stimulated genes and phospho-proteins also supports STING activation, which is abolished in cGAS knockout cells. Co-culture of THP-1 macrophages with MDA-MB-231 cells in paclitaxel, or conditioned media from MDA-MB-231 cells pre-treated with paclitaxel, polarizes THP-1 cells from an M0 to M1 phenotype. Furthermore, we observe an increase in micronuclei and TILs after paclitaxel for 3 of 4 patient samples with one patient converting from a plasma cell-rich to a lymphocyte-rich infiltrate. Conclusions: Physiologic levels of paclitaxel can generate micronuclei to activate the cGAS-STING pathway in breast cancer cell lines and to induce a pro-inflammatory interferon-beta driven response. This may present a post-mitotic mechanism for paclitaxel-mediated cancer cell death. These data may provide the mechanistic basis for the high efficacy seen in combining taxanes with immunotherapies. Citation Format: Yang Hu, Ning Jin, Baraa K. Manasrah, Stephanie M. McGregor, Christina Scribano, John B. Tucker, Rachel Yan, Robert F. Lera, Beth A. Weaver, Mark E. Burkard. Paclitaxel-induced micronucleation activates pro-inflammatory cGAS/STING signaling in triple negative breast cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2248.

Paclitaxel Enhances the Innate Immunity by Promoting NLRP3 Inflammasome Activation in Macrophages

Activation of NLRP3 inflammasome in peripheral nerve contributes to paclitaxel-induced neuropathic pain

Paclitaxel acts as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice.

Abstract 2248: Paclitaxel-induced micronucleation activates pro-inflammatory cGAS/STING signaling in triple negative breast cancer

Tubulin acetylation enhances lung cancer resistance to paclitaxel-induced cell death through Mcl-1 stabilization

Data from Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory Cgas–sting Signaling in Triple-Negative Breast Cancer

Prevention of Paclitaxel-Induced Allodynia by Minocycline: Effect on Loss of Peripheral Nerve Fibers and Infiltration of Macrophages in Rats

Inhibition of NLRP3 inflammasome contributes to paclitaxel efficacy in triple negative breast cancer treatment

Paclitaxel alleviated sepsis-induced acute lung injury by activating MUC1 and suppressing TLR-4/NF-κB pathway.

CX3CL1-mediated Macrophage Activation Contributed to Paclitaxel-Induced DRG Neuronal Apoptosis and Painful Peripheral Neuropathy

Excipient of paclitaxel induces metabolic dysregulation and unfolded protein response

IκB Kinase Activation is Involved in Regulation of Paclitaxel-Induced Apoptosis in Human Tumor Cell Lines

Nuclear Factor-Kappab/ikappab Signaling Pathway May Contribute to the Mediation of Paclitaxel-Induced Apoptosis in Solid Tumor Cells.

Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy

Role of Tumor Necrosis Factor Alpha-Induced Protein 1 in Paclitaxel Resistance.

AKAP150 involved in paclitaxel-induced neuropathic pain via inhibiting CN/NFAT2 pathway and downregulating IL-4.

Up-regulation of CX3CL1 Via Nuclear Factor-κB–dependent Histone Acetylation is Involved in Paclitaxel-induced Peripheral Neuropathy

Paclitaxel Promotes Tumor-Infiltrating Macrophages in Breast Cancer.

[miR-99b-5p inhibits the activation of NLRP3 inflammasome to alleviate the neurotoxicity induced by paclitaxel chemotherapy]

End-binding protein 1 stimulates paclitaxel sensitivity in breast cancer by promoting its actions toward microtubule assembly and stability

Differential Impairment of Regulatory T Cells Rather Than Effector T Cells by Paclitaxel-Based Chemotherapy.